We are a clinical stage biopharmaceutical company focused on developing innovative therapeutics to improve the lives of patients with neurological disorders.
Building upon our extensive knowledge of human genetics and diseases caused by mutations in ion channels, known as channelopathies, we are advancing – both independently and with our pharmaceutical collaborators – a novel product pipeline of ion channel modulators to address therapeutic areas of high unmet medical need, such as pain and epilepsy.
On September 6, 2018, we hosted a webcast providing an overview of the addition of XEN496 to our clinical pipeline.Read More
Xenon to Present at the Stifel 2018 Healthcare Conference
November 7, 2018
Xenon Pharmaceuticals Announces Proposed Public Offering of Common Shares
September 12, 2018